Takeda’s zasocitinib proves ‘top-notch’ for difficult-to-treat psoriasis in phase 3 update

Takeda has unveiled more data from its phase 3 trials of zasocitinib, demonstrating that the once-daily pill was able to clear or almost clear scalp psoriasis in 75% of patients.